美女免费一级视频在线观看

If you ask the leaders at Eversana, the medical marketing world might be forever changed from here on out. 

On Thursday, the 2025 MM+M Agency 100 honoree debuted its AI Agency tool in collaboration with Google Cloud at the tech giant’s Chelsea offices in New York. 

The tool is described as an end-to-end full service agency that claims to do “a year’s worth of work in 10 minutes,” according to Shane Mayer, Eversana Intouch’s EVP, tech and transformation. 

Mayer later clarified that 10 minutes actually meant more like 30 minutes, yet underscored the power of the tool. 

“You can still juxtapose that to the traditional agency timelines,” he said. 

During the hour-long presentation, Eversana and Google representatives touched on a few key points about the product and how it can impact the medical marketing industry. 

First, the representatives stressed that the AI tool uses AI agents as opposed to a large language model — with Abid Rahman, SVP of innovation at Eversana, highlighting the difference. 

He said these tools are “distinct,” “discrete” and ultimately trained to do different things. Unlike large language models, he said the AI Agency doesn’t simply prompt Google Gemini and receive a general answer.

“These agents are trained to be very specific to what they’re supposed to know about and what they’re supposed to do. Think of them as experts,” he said. “They are not just robots. They’re actually thinking and doing intelligent things behind the scenes. They’re grounded in real data.”

Second, as an end-to-end service, the tool is broken down into various sections, where users are able to get information from each step of the project lifecycle. 

The three agent “buckets” the tool features includes “Business Strategy Agents,” “Omnichannel Agents” and “Content Creation Agents.” 

The business strategy agents include competitive products agents, profile products agents, sentiment analysis agents, branding positioning agents and more. 

The omnichannel agents are meant to guide users through patient journeys, experience arcs, message map agents and channel mix agents. 

The content creation agents include production agents, creative asset agents, video agents and image agents.

During the demonstration, the representatives showed an ad campaign and an AI influencer video created with the tool, noting that the language and content featured in the advertisements were in line with pharma regulations. 

Notably, AI Agency was launched months after Eversana unveiled its Eversana Orchestrate MLR offering.

Eversana’s chief innovation officer and Eversana Intouch’s CEO Faruk Capan also emphasized that while the tool serves as an end-to-end agency, it still requires expertise of a team to guide the content. 

The team would be much leaner in size than what clients typically see at traditional agencies, he noted, but would have the knowledge to respond or fix any content developed by the AI. 

“We are responding to the wishes of our clients,” said Capan, who mentioned that these pharma clients have been asking to work with smaller teams. “We would rather be the first ones to try to develop this product and learn from it.”

As the team built the tool in collaboration with Google, the team had access to research from Google’s DeepMind team and built the platform using software development kits from the company. 

Despite this, Capan emphasized that the data uploaded by clients to the platform remains with the users and is not shared with the Eversana or Google teams. 

John Clarkson, SVP of strategic development at Eversana Intouch, reiterated the company’s belief that the tool is the future of the agency world.

He also emphasized how humans will remain an integral part of the tool’s output. 

“You just saw the end-to-end demo of how we’re leveraging AI for 80% of all of that creation, but the remaining 20% is human in the loop — absolutely, positively essential. It always has been. It always will be,” he said. 

The combination of AI capabilities and human input, he said, makes a “tremendous difference when it comes to speed and precision” for pharma clients. 

Capan said that the team has been using the product for the last six months, and that some of the agency’s clients have been using the tool for specific output needs. 

The tool is currently live and he added that the team plans to sell it as a full-service offering, though it could be used for specific precision verticals to assist with work.